Literature DB >> 12615877

Spain14-5 international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics.

Emilio Pérez-Trallero1, José M Marimón, Alberto Gonzalez, Luis Iglesias.   

Abstract

The Spain(14)-5 international multiresistant clone was initially described as resistant to penicillin, tetracycline, chloramphenicol and trimethoprim/sulfamethoxazole. In Gipuzkoa, Spain, Streptococcus pneumoniae isolated from 16 patients, and determined by PFGE and multilocus sequence typing to belong to the Spain(14)-5 clone, showed further resistance to fluoroquinolones (all strains had point mutations in the parC and gyrA genes). In addition, most strains showed resistance to amoxicillin (MIC > or = 8 mg/L), cefotaxime (MIC > or = 2 mg/L), macrolides and lincosamides. Two strains were resistant to rifampicin (MIC 8 mg/L). The multiresistance observed in these isolates converts the Spain(14)-5 clone into one of the most, if not the most, multiresistant of the international clones described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615877     DOI: 10.1093/jac/dkg106

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin.

Authors:  E Pérez-Trallero; J M Marimón; A González; C García-Rey; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Clinical Isolates of the Spain14-5 clone of Streptococcus pneumoniae carry a recombinant rpoB gene.

Authors:  M J Ferrándiz; E Pérez-Trallero; J M Marimón; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Authors:  Ralf René Reinert; Susanne Reinert; Mark van der Linden; Murat Y Cil; Adnan Al-Lahham; Peter Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals.

Authors:  María José Ferrándiz; Carmen Ardanuy; Josefina Liñares; José María García-Arenzana; Emilia Cercenado; Ana Fleites; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.

Authors:  Mathias W R Pletz; Lesley McGee; James Jorgensen; Bernard Beall; Richard R Facklam; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  E Pérez-Trallero; J M Marimon; M Ercibengoa; D Vicente; E G Pérez-Yarza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-20       Impact factor: 3.267

7.  Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.

Authors:  Adela G de la Campa; Luz Balsalobre; Carmen Ardanuy; Asunción Fenoll; Emilio Pérez-Trallero; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

8.  Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.

Authors:  Emilio Pérez-Trallero; José M Marimon; Luis Iglesias; Julián Larruskain
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

9.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.